Cancer Therapy Related Diarrhea - Pipeline Insight, 2024

This “Cancer Therapy Related Diarrhea - Pipeline Insight, 2024,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Cancer Therapy Related Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cancer Therapy Related Diarrhea Understanding

Cancer Therapy Related Diarrhea: Overview

Cancer Therapy Related Diarrhea is a common problem, especially in patients with advanced cancer. It is one of the main drawbacks for cancer patients. In oncological patients, diarrhea can occur in several different situations. Possible causes could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections and has to be carefully differentiated from other causes of diarrhea. Cancer therapy related diarrhea can cause depletion of fluids and electrolytes, malnutrition, dehydration and hospitalization, all of which can lead to cardiovascular compromise and death. In addition, diarrhea can interfere with and detract from cancer treatment by causing dosing delays or reductions which may have an impact on survival.

Symptoms
The symptoms of Cancer Therapy Related Diarrhea include:

• Dehydration
• Dizzy or light headed
• Fever
• Dark yellow urine or not urinating

Diagnosis
Diagnosis of Cancer Therapy Related Diarrhea begins with a history to determine the severity according to the National Cancer Institute Common Toxicity grades. The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role.

Treatment
The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization. Initial nonpharmacologic measures include avoidance of foods that would aggravate the diarrhea and aggressive oral rehydration with fluids that contain water, salt, and sugar. loperamide, octreotide and tincture of opium are recommended in the updated treatment guidelines by the consensus conference on the management of Cancer Therapy Related Diarrhea.

Cancer Therapy Related Diarrhea Emerging Drugs Chapters

This segment of the Cancer Therapy Related Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cancer Therapy Related Diarrhea Emerging Drugs

Crofelemer: Napo Pharmaceuticals Crofelemer is a drug that is a chloride channel antagonist and is presently being studied in Phase III of clinical trial. Originally, this compound was owned by Shaman Pharmaceuticals and currently under the development of Napo Pharmaceuticals.

Cancer Therapy Related Diarrhea: Therapeutic Assessment

This segment of the report provides insights about the different Cancer Therapy Related Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cancer Therapy Related Diarrhea

There are approx. 2+ key companies which are developing the therapies for Cancer Therapy Related Diarrhea. The companies which have their Cancer Therapy Related Diarrhea drug candidates in the most advanced stage, i.e. phase III include, Napo Pharmaceuticals.

Phases

This report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cancer Therapy Related Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cancer Therapy Related Diarrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Therapy Related Diarrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Therapy Related Diarrhea drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Therapy Related Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Therapy Related Diarrhea.

Cancer Therapy Related Diarrhea Report Insights

• Cancer Therapy Related Diarrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cancer Therapy Related Diarrhea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cancer Therapy Related Diarrhea drugs?
• How many Cancer Therapy Related Diarrhea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Therapy Related Diarrhea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cancer Therapy Related Diarrhea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cancer Therapy Related Diarrhea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Napo Pharmaceuticals

Key Products

• Crofelemer

This product will be delivered within 1-3 business days.